Posts tagged HBV
Arbutus, Spring Bank in HBV collaboration

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV).

Read More
Arbutus updates HBV Phase 2 trial

Arbutus Biopharma (NASDAQ:ABUS) reported new results from the ongoing Phase 2 study of ARB-1467 in chronically infected HBV patients on stable nucleoside therapy, and plans to add a fourth cohort of patients to the trial.

Read More
ContraVir updates action of HBV inhibitor

ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X protein (HBx) and host cyclophilin A, with nanomolar potency. 

Read More
WB downgrades Arrowhead Pharma to MP

William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday.

Read More
WB ups Arrowhead Pharma price target to $12

William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN).

Under the accord, Arrowhead would receive an up-front fee of $35-million and $21.5-million in equity, and up to $617-million in options and milestones, plus royalties.

Read More
WB starts 4 chronic Hep B biotechs at outperform

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier.

“Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each in cumulative global sales over a span of two decades,” writes analyst Katherine Xu.

Read More
ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals.

Under the accord, ContraVir will acquire all of the outstanding equity interests in Ciclofilin for the right to receive future milestone payments, which will be allocated among the holders of Ciclofilin common stock.

Read More
Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert.

The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in the viral life cycle, he said.

Read More
Maxim starts ContraVir Pharma at buy

Maxim Group has initiated coverage of ContraVir Pharmaceuticals (NASDAQ:CTRV) with a “buy” rating and price target of $4, calling the company an emerging anti-viral leader with two clean shots on goal. The stock closed at 97 cents on Thursday.

“ContraVir has two programs: one in shingles (Phase 3) and one in hepatitis B (Phase 1/2), both of which can be value drivers for the company,” writes analyst Jason Kolbert.

Read More